螺内酯对心力衰竭高风险人群心血管功能及纤维化标志物的影响:HOMAGE随机临床试验
HOMAGE随机开放标签盲终点试验纳入527例冠心病或高危且B型利钠肽升高者,比较螺内酯50 mg/日与对照最长9个月。主要终点基线血清半乳糖凝集素-3与Ⅲ型前胶原氨基端前肽变化的交互作用未达显著,但螺内酯组Ⅰ型前胶原羧基端前肽及PICP/CITP比值显著降低,收缩压、左房容积和NT-proBNP亦下降。
要点
- 螺内酯未通过半乳糖凝集素-3识别胶原标志物更大降幅。
- 螺内酯显著降低PICP及PICP/CITP比值,可能影响Ⅰ型胶原代谢。
- 螺内酯降低收缩压、左房容积和NT-proBNP,能否延缓症状性心衰待研究。
核心结论
- 半乳糖凝集素-3未能识别螺内酯应答中胶原标志物更大降幅的人群。
- 螺内酯可能影响Ⅰ型胶原代谢,并降低收缩压、左房容积和NT-proBNP。
- 螺内酯能否延缓或预防进展为症状性心衰尚需进一步研究。
研究设计与样本
- 随机、开放标签、盲终点试验,比较螺内酯50 mg/日或对照最长9个月。
- 纳入患有冠心病或高危且血浆B型利钠肽升高者,共527例,中位年龄73岁,女性26%。
主要发现
- PIIINP变化在螺内酯组与对照组相似(平均差-0.15;95%CI -0.44至0.15 μg/L;P=0.32)。
- 螺内酯组PICP降幅更大(平均差-8.1;95%CI -11.9至-4.3 μg/L;P<0.0001)。
- 螺内酯组PICP/CITP比值降幅更大(平均差-2.9;95%CI -4.3至-1.5;P<0.0001)。
- 未观察到与血清半乳糖凝集素-3的交互作用。
- 螺内酯组收缩压(平均差-10;95%CI -13至-7 mmHg;P<0.0001)、左房容积(平均差-1;95%CI -2至0 mL/m2;P=0.010)和NT-proBNP(平均差-57;95%CI -81至-33 ng/L;P<0.0001)降低。
临床怎么用
- 对于冠心病或高危且利钠肽升高者,螺内酯可能改善Ⅰ型胶原代谢相关标志物。
- 螺内酯可降低收缩压、左房容积和NT-proBNP,但延缓症状性心衰的获益尚未证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure. METHODS AND RESULTS: Randomized, open-label, blinded-endpoint trial comparing spironolactone (50 mg/day) or control for up to 9 months in people with, or at high risk of, coronary disease and raised plasma B-type natriuretic peptides. The primary endpoint was the interaction between baseline serum galectin-3 and changes in serum procollagen type-III N-terminal pro-peptide (PIIINP) in participants assigned to spironolactone or control. Procollagen type-I C-terminal pro-peptide (PICP) and collagen type-1 C-terminal telopeptide (CITP), reflecting synthesis and degradation of type-I collagen, were also measured. In 527 participants (median age 73 years, 26% women), changes in PIIINP were similar for spironolactone and control [mean difference (mdiff): -0.15; 95% confidence interval (CI) -0.44 to 0.15 μg/L; P = 0.32] but those receiving spironolactone had greater reductions in PICP (mdiff: -8.1; 95% CI -11.9 to -4.3 μg/L; P < 0.0001) and PICP/CITP ratio (mdiff: -2.9; 95% CI -4.3 to -1.5; <0.0001). No interactions with serum galectin were observed. Systolic blood pressure (mdiff: -10; 95% CI -13 to -7 mmHg; P < 0.0001), left atrial volume (mdiff: -1; 95% CI -2 to 0 mL/m2; P = 0.010), and NT-proBNP (mdiff: -57; 95% CI -81 to -33 ng/L; P < 0.0001) were reduced in those assigned spironolactone. CONCLUSIONS: Galectin-3 did not identify greater reductions in serum concentrations of collagen biomarkers in response to spironolactone. However, spironolactone may influence type-I collagen metabolism. Whether spironolactone can delay or prevent progression to symptomatic heart failure should be investigated.
引用
- Cleland JGF, Ferreira JP, Mariottoni B, et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2021. PMID: 33215209. doi:10.1093/eurheartj/ehaa758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。